ERBB2 and glioblastoma: Interestingly, no dose-related toxicity was observed in the first ongoing phase I clinical trial CAR2BRAIN (NCT03383978) using intrathecally administered HER2-specific-CAR-NK-92 cells against recurrent HER2+GBM [52].